A Phase 3 interventional study of 0.5mg DRSP / 0.5mg E2 (BAY86-4891) and 0.25mg DRSP / 0.5mg E2 (BAY86-4891) in Vasomotor Symptoms and Hot Flashes, sponsored by Bayer. Completed at 76 sites in United States. Open to female participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2015-05-06.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing estradiol in Hot Flashes — none open to participants now, none under way, none of them phase 3. Estradiol · Hot Flashes.
Among the 13 studies testing estradiol in Hot Flashes, this one is the 3rd largest by enrollment, is one of 4 that started in 2007, is one of 8 in phase 3, and was the 6th registered.
339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.
Browse Hot Flashes studies →None of the 13 studies testing estradiol in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →
Estradiol: first FDA approval 1954 (DELESTROGEN), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 40 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 9 · Phase 4 1
First in 2003; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 735 is above the median of 90 across 306 interventional studies indexed under Hot Flashes.
Median enrollment 431 across the 13 interventional studies. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 13 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
18 studies in Hot Flashes by Bayer: none open now, 1 under way, 1 of them phase 3. Of 17 finished, 7 (41%) have results posted.
Among the 18 studies in Hot Flashes by Bayer, this one has the largest enrollment, is one of 3 that started in 2007, is one of 7 in phase 3, and was the 3rd registered.
Bayer’s Hot Flashes studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing estradiol in Hot Flashes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 18 in Hot Flashes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the lowest effective dose of the study drug for the relief of moderate to severe vasomotor symptoms in postmenopausal women for 12 weeks.
This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.
Bayer HealthCare Pharmaceuticals, Inc. is the sponsor of the trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One tablet \[0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
Drug: 0.5mg DRSP / 0.5mg E2 (BAY86-4891)
One tablet \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
Drug: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)
One tablet \[17β-estradiol (E2 0.3mg)\] per day taken orally for 3 cycles (28 days per cycle).
Drug: Estradiol (E2 0.3mg)
Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
Drug: Placebo
Drug pages: Drospirenone · Estradiol
One tablet \[0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
Drug pages: Drospirenone · Estradiol
One tablet \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
One tablet \[17β-estradiol (E2 0.3mg)\] per day taken orally for 3 cycles (28 days per cycle).
Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)
Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 12 number of moderate to severe hot flushes minus baseline number.
Time frame: Baseline until 12 weeks of treatment
Change From Baseline to Week 4 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)
Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 4 number of moderate to severe hot flushes minus baseline number.
Time frame: Baseline until 4 weeks of treatment
Change From Baseline to Week 12 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value)
Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as \[(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)\] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 12 severity of moderate to severe hot flushes minus baseline severity.
Time frame: Baseline until 12 weeks of treatment
Change From Baseline to Week 4 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value)
Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as \[(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)\] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 4 severity of moderate to severe hot flushes minus baseline severity.
Time frame: Baseline until 4 weeks of treatment
Change From Baseline to Week 12 in Vaginal pH
Vaginal pH determined following speculum examination using vaginal pH paper and recorded on case report form (CRF). Absolute change calculated as week 12 pH minus baseline pH.
Time frame: Baseline until 12 weeks of treatment
Change From Baseline to Week 12 in Vaginal Maturation Value
Calculated as (percentage of superficial cells) + 0.5 \* (percentage of intermediate cells). Absolute change calculated as week 12 value minus baseline value.
Time frame: Baseline until 12 weeks of treatment
Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Dryness'
Subjects self-assessed symptom severity
Time frame: After 12 weeks of treatment
Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal and/or Vulvar Irritation/Itching'
Subjects self-assessed symptom severity
Time frame: After 12 weeks of treatment
Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Dysuria'
Subjects self-assessed symptom severity
Time frame: After 12 weeks of treatment
Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Pain Associated With Sexual Activity'
Subjects self-assessed symptom severity
Time frame: After 12 weeks of treatment
Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Bleeding Associated With Sexual Activity'
Subjects self-assessed symptom severity
Time frame: After 12 weeks of treatment
Urogenital Symptoms: Number of Participants With Symptom 'Frequent Urination'
Subjects self-assessed presence or absence of symptom
Time frame: After 12 weeks of treatment
Urogenital Symptoms: Number of Participants With Symptom 'Involuntary Urination When Laughing or Coughing'
Subjects self-assessed presence or absence of symptom
Time frame: After 12 weeks of treatment
Urogenital Symptoms: Number of Participants With Symptom 'Urination at Night'
Subjects self-assessed presence or absence of symptom; and if present recorded average number of times per night: 1; 2 to 4; more than 4.
Time frame: After 12 weeks of treatment
Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Mean Value)
Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 12 number of moderate to severe hot flushes minus baseline number.
Time frame: Baseline until 12 weeks of treatment
Change From Baseline to Week 4 in Weekly Frequency of Moderate to Severe Hot Flushes (Mean Value)
Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 4 number of moderate to severe hot flushes minus baseline number.
Time frame: Baseline until 4 weeks of treatment
Change From Baseline to Week 12 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Mean Value)
Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as \[(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)\] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 12 severity moderate to severe hot flushes minus baseline severity.
Time frame: Baseline until 12 weeks of treatment
Change From Baseline to Week 4 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Mean Value)
Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as \[(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)\] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 4 severity moderate to severe hot flushes minus baseline severity.
Time frame: Baseline until 4 weeks of treatment
The study was conducted at 79 centers in the United States from 26 Mar 2007 (date of first participant's first visit) to 03 Nov 2008 (date of last participant's last visit)
| Milestone | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo |
|---|---|---|---|---|
| Started | 183 | 184 | 185 | 183 |
| Participants received treatment | 181 | 183 | 182 | 180 |
| Baseline and postdose vms data available | 178 | 177 | 179 | 176 |
| Completed | 160 | 164 | 158 | 153 |
| Not completed | 23 | 20 | 27 | 30 |
| Withdrew: Adverse event | 7 | 4 | 6 | 4 |
| Withdrew: Lost to follow-up | 4 | 5 | 2 | 6 |
| Withdrew: Protocol violation | 1 | 2 | 1 | 3 |
| Withdrew: Withdrawal by subject | 2 | 5 | 9 | 10 |
| Withdrew: Site termination | 2 | 0 | 0 | 1 |
| Withdrew: Randomization in error | 2 | 0 | 1 | 1 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 1 |
| Withdrew: Non-compliant with study drug | 1 | 0 | 5 | 0 |
| Withdrew: Non-compliant with visit schedule | 1 | 1 | 1 | 2 |
| Withdrew: Hormone fear | 0 | 0 | 0 | 1 |
| Withdrew: Lost interest in study participation | 0 | 1 | 0 | 0 |
| Withdrew: In-/exclusion criterion violated | 2 | 1 | 2 | 1 |
| Withdrew: Move | 0 | 1 | 0 | 0 |
Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 12 number of moderate to severe hot flushes minus baseline number.
| Hot Flushes per week | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo |
|---|---|---|---|---|
| Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value) | -54.515 (-324.6 to 60.82) | -54.125 (-215.9 to 9.03) | -44.389 (-145.4 to 91.25) | -30.020 (-485.3 to 55.91) |
Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 4 number of moderate to severe hot flushes minus baseline number.
| Hot Flushes per week | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo |
|---|---|---|---|---|
| Change From Baseline to Week 4 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value) | -46.868 (-276.63 to 60.82) | -37.596 (-162.15 to 35.00) | -31.621 (-141.44 to 37.91) | -15.109 (-666.33 to 27.17) |
Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as \[(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)\] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 12 severity of moderate to severe hot flushes minus baseline severity.
| Scores on a scale | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo |
|---|---|---|---|---|
| Change From Baseline to Week 12 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value) | -1.9294 (-3.000 to 0.480) | -1.000 (-3.000 to 0.443) | -0.2638 (-3.000 to 0.337) | -0.0698 (-3.000 to 0.542) |
Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as \[(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)\] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 4 severity of moderate to severe hot flushes minus baseline severity.
| Scorese on a scale | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo |
|---|---|---|---|---|
| Change From Baseline to Week 4 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value) | -0.2905 (-3.000 to 0.383) | -0.1821 (-2.800 to 1.267) | -0.0651 (-2.898 to 0.380) | 0.0000 (-3.000 to 0.516) |
Vaginal pH determined following speculum examination using vaginal pH paper and recorded on case report form (CRF). Absolute change calculated as week 12 pH minus baseline pH.
| (pH) | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo |
|---|---|---|---|---|
| Change From Baseline to Week 12 in Vaginal pH | -0.63 ± 0.874 | -0.63 ± 0.935 | -0.66 ± 0.967 | -0.06 ± 0.698 |
Calculated as (percentage of superficial cells) + 0.5 \* (percentage of intermediate cells). Absolute change calculated as week 12 value minus baseline value.
| Percentages of cells | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo |
|---|---|---|---|---|
| Change From Baseline to Week 12 in Vaginal Maturation Value | 10.07 ± 28.638 | 11.71 ± 29.185 | 7.69 ± 25.627 | -2.41 ± 20.923 |
Subjects self-assessed symptom severity
| participants | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo |
|---|---|---|---|---|
| none | 83 | 70 | 71 | 70 |
| mild | 59 | 52 | 62 | 47 |
| moderate | 24 | 38 | 29 | 35 |
| severe | 6 | 11 | 10 | 12 |
Subjects self-assessed symptom severity
| participants | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo |
|---|---|---|---|---|
| none | 152 | 140 | 146 | 128 |
| mild | 20 | 24 | 21 | 22 |
| moderate | 0 | 3 | 5 | 11 |
| severe | 0 | 4 | 0 | 3 |
Subjects self-assessed symptom severity
| participants | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo |
|---|---|---|---|---|
| none | 166 | 169 | 167 | 153 |
| mild | 6 | 2 | 1 | 9 |
| moderate | 0 | 0 | 1 | 0 |
| severe | 0 | 0 | 1 | 0 |
Subjects self-assessed symptom severity
| participants | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo |
|---|---|---|---|---|
| none | 128 | 132 | 127 | 118 |
| mild | 21 | 22 | 21 | 19 |
| moderate | 13 | 7 | 11 | 11 |
| severe | 4 | 4 | 3 | 4 |
Subjects self-assessed symptom severity
| participants | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo |
|---|---|---|---|---|
| none | 164 | 162 | 159 | 151 |
| mild | 2 | 2 | 3 | 2 |
| moderate | 0 | 1 | 0 | 0 |
| severe | 0 | 0 | 0 | 0 |
Subjects self-assessed presence or absence of symptom
| participants | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo |
|---|---|---|---|---|
| Urogenital Symptoms: Number of Participants With Symptom 'Frequent Urination' | 45 | 56 | 62 | 57 |
Subjects self-assessed presence or absence of symptom
| participants | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo |
|---|---|---|---|---|
| Urogenital Symptoms: Number of Participants With Symptom 'Involuntary Urination When Laughing or Coughing' | 70 | 53 | 53 | 48 |
Subjects self-assessed presence or absence of symptom; and if present recorded average number of times per night: 1; 2 to 4; more than 4.
| participants | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo |
|---|---|---|---|---|
| Urogenital Symptoms: Number of Participants With Symptom 'Urination at Night' | 99 | 114 | 114 | 111 |
Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 12 number of moderate to severe hot flushes minus baseline number.
| Hot Flushes per week | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo |
|---|---|---|---|---|
| Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Mean Value) | -60.331 ± 37.5217 | -55.317 ± 30.2311 | -41.783 ± 32.6122 | -31.916 ± 44.4507 |
Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 4 number of moderate to severe hot flushes minus baseline number.
| Hot Flushes per week | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo |
|---|---|---|---|---|
| Change From Baseline to Week 4 in Weekly Frequency of Moderate to Severe Hot Flushes (Mean Value) | -48.810 ± 35.7876 | -38.989 ± 27.7812 | -32.633 ± 28.1349 | -24.195 ± 54.7480 |
Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as \[(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)\] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 12 severity moderate to severe hot flushes minus baseline severity.
| Scores on a scale | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo |
|---|---|---|---|---|
| Change From Baseline to Week 12 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Mean Value) | -1.4473 ± 1.11616 | -1.2141 ± 1.08299 | -0.7822 ± 1.03497 | -0.3873 ± 0.76950 |
Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as \[(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)\] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 4 severity moderate to severe hot flushes minus baseline severity.
| scores on a scale | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo |
|---|---|---|---|---|
| Change From Baseline to Week 4 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Mean Value) | -0.8347 ± 1.02226 | -0.5859 ± 0.89106 | -0.4033 ± 0.73774 | -0.1926 ± 0.63585 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | — | 0/181 (0%) | 80/181 (44.2%) |
| 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | — | 1/183 (0.5%) | 75/183 (41%) |
| Estradiol (E2 0.3mg) | — | 3/182 (1.6%) | 68/182 (37.4%) |
| Placebo | — | 1/180 (0.6%) | 64/180 (35.6%) |
| Event | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo |
|---|---|---|---|---|
| Road traffic accidentInjury, poisoning and procedural complications | 0/181 | 0/183 | 0/182 | 1/180 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/181 | 0/183 | 1/182 | 0/180 |
| Oropharyngeal cancer stage unspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/181 | 0/183 | 1/182 | 0/180 |
| Ovarian cystReproductive system and breast disorders | 0/181 | 0/183 | 1/182 | 0/180 |
| Uterine polypReproductive system and breast disorders | 0/181 | 0/183 | 1/182 | 0/180 |
| SalpingitisInfections and infestations | 0/181 | 1/183 | 0/182 | 0/180 |
| Event | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo |
|---|---|---|---|---|
| Breast tendernessReproductive system and breast disorders | 12/181 | 6/183 | 1/182 | 0/180 |
| HeadacheNervous system disorders | 8/181 | 11/183 | 10/182 | 9/180 |
| Low density lipoprotein increasedInvestigations | 4/181 | 7/183 | 7/182 | 9/180 |
| Abdominal painGastrointestinal disorders | 2/181 | 8/183 | 5/182 | 1/180 |
| Cervical dysplasiaReproductive system and breast disorders | 2/181 | 8/183 | 5/182 | 7/180 |
| Vaginitis bacterialInfections and infestations | 7/181 | 3/183 | 7/182 | 7/180 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 4/181 | 4/183 | 1/182 | 7/180 |
| Back painMusculoskeletal and connective tissue disorders | 7/181 | 2/183 | 4/182 | 3/180 |
| NasopharyngitisInfections and infestations | 4/181 | 6/183 | 4/182 | 6/180 |
| Upper respiratory tract infectionInfections and infestations | 6/181 | 3/183 | 4/182 | 3/180 |
| Age, Continuous(years) | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 53.8 ± 5.61 | 53.5 ± 5.77 | 53.3 ± 6.05 | 53.4 ± 6.46 | 53.5 ± 5.97 |
| Sex: Female, Male(Participants) | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo | Total |
|---|---|---|---|---|---|
| Female | 178 | 177 | 179 | 176 | 710 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Number of participants with hysterectomy/oophorectomy(Participants) | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo | Total |
|---|---|---|---|---|---|
| hysterectomized | 98 | 91 | 98 | 99 | 386 |
| oophorectomized | 61 | 61 | 63 | 59 | 244 |
| Body Mass Index (BMI)(kg/sqm) | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 29.070 ± 6.0636 | 28.190 ± 5.6965 | 29.080 ± 5.7410 | 27.882 ± 5.7859 | 28.543 ± 5.8370 |
| Years since last menstruation at baseline(years) | 0.5mg DRSP / 0.5mg E2 (BAY86-4891) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | Estradiol (E2 0.3mg) | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 9.913 ± 8.6719 | 8.784 ± 7.9947 | 9.214 ± 8.1892 | 9.509 ± 8.9693 | 9.355 ± 8.4560 |
The record gives a start of Mar 2007, a primary completion of Oct 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 3 years 6 months after primary completion. A results delay was requested in Dec 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Drospirenone · Estradiol